Showing 241-250 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-August-2022 to 31-July-2025 | $699,995.75 |
| Improving pig islet transplant efficacy in a preclinical baboon diabetes model with induced immune tolerance to the xenografts | Trustees of Columbia University in the City of New York | Megan Sykes | Cures | 01-June-2024 to 31-May-2026 | $599,999.94 |
| Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes | Trustees of Columbia University in the City of New York | Camillo Bechi Genzano | Cures | 01-March-2025 to 29-February-2028 | $256,285.00 |
| Safety and Efficacy of Adjunct Therapies in Adults with Type 1 diabetes: multicenter, registry-based study | Trustees of Indiana University | Viral Shah | Improving Lives | 01-September-2025 to 31-August-2028 | $1,603,777.39 |
| CGM-Derived Glucose Dynamic Index as Diagnostic Marker for Progression to Type 1 Diabetes | Trustees of Indiana University | Viral Shah | Cures | 01-November-2024 to 31-October-2027 | $900,000.00 |
| SOLUBLE LYMPHOCYTE ACTIVATION GENE-3 (s-LAG-3): A POTENTIAL SURROGATE MARKER FOR TYPE-1 DIABETES PROGRESSION AND IMMUNOTHERAPY SUCCESS | Trustees of Indiana University | Jon Piganelli | Cures | 01-July-2025 to 30-June-2026 | $153,000.00 |
| Type I Interferons and B Cell Metabolism as Drivers of Type 1 Diabetes | Trustees of Indiana University | Jamie Felton | Cures | 01-February-2026 to 31-January-2029 | $682,534.00 |
| Targeting type 1 Diabetes through Polyamines with DFMO | Trustees of Indiana University | Emily Sims | Cures | 01-October-2022 to 30-September-2026 | $3,693,701.00 |
| Optimizing Approaches to Type 1 Diabetes Prediction and Intervention in the Adult Autoantibody Positive Population | Trustees of Indiana University | Emily Sims | Cures | 01-February-2026 to 31-January-2029 | $691,694.00 |
| Defining the role of islet-derived extracellular vesicle PD-L1 cargo in type-1 diabetes | Trustees of Indiana University | Chaitra Rao | Cures | 01-March-2024 to 30-April-2027 | $228,537.45 |